"Registration is planned before the end of this year," - quoted by RIA Novosti press service.

Earlier it was reported that the Institute of Immunology FMBA submitted documents for registration of the drug from COVID-19 "MIR 19".

The first phase of human clinical trials was completed in March this year and showed the safety of MIR 19.